About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/15/2021.

Efficacy of Zoledronic Acid + Colaren vs Zoledronic Acid + Conventional Treatment for Osteoporosis in HIV+ and HIV- Men

Clinicaltrials.gov identifier NCT03930992

Recruitment Status Recruiting

First Posted April 29, 2019

Last update posted April 30, 2019

Study Description

Brief summary:

Clinical trial to assess the effectiveness of the supplement Colaren® associated with zoledronic acid 4mg/annually in the treatment of osteoporosis secondary, compared to standard treatment plus zoledronic acid 4mg/annually. The standard treatment will include 1gr of calcium/day and vitamin D supplement. In both cases, vitamin D levels will be determinated, which should remain at more than 30 ng/mL. Including men with osteoporosis secondary to HIV and men with osteoporosis secondary to any other cause (HIV negative). Vitamin D levels, bone densitometry and markers of metabolism, bone formation and bone resorption will be assessment. The all parameters above will be assessed basally (before the start of treatment), after starting the treatment, an assessment will be made at 12 weeks where vitamin D levels and bone markers will be measured. Meanwhile, at week 24 assess only vitamin D levels; and finally, at week 52 all parameters mentioned above will be measured.

  • Condition or Disease:Secondary Osteoporosis
  • Intervention/Treatment: Drug: Colaren in HIV positive
    Drug: standard treatment in HIV positive
    Drug: Colaren in HIV negative
    Drug: standard treatment in HIV negative
  • Phase: Phase 3
Detailed Description

This study is a clinical trial to assess the effectiveness of the supplement Colaren® associated with annually zoledronic acid 4mg, in the treatment of osteoporosis secondary or not to HIV infection, compared to standard treatment plus zoledronic acid 4mg/annually. The standard treatment will include 1gr of calcium/day and vitamin D supplement. In both cases, vitamin D levels will be evaluated, which should remain at more than 30 ng/mL. Including men with osteoporosis secondary to HIV and men with osteoporosis secondary to any other cause (HIV negative). Vitamin D levels, bone densitometry and markers of metabolism, bone formation and bone resorption will be assessment. The all parameters above will be assessed basally (before the start of treatment), after starting the treatment, an assessment will be made at 12 weeks where vitamin D levels and bone markers will be measured. Meanwhile, at week 24 assess only vitamin D levels; and finally, at week 52 all parameters mentioned above will be measured.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 1 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Intervention Model Description: Study type: Interventional, with four arms: arm: 4 mg zoledronic acid annually plus colaren ® in HIV-positive; arm: 4 mg zoledronic acid annually plus conventional treatment in HIV-positive; arm: 4 mg zoledronic acid annually plus colaren ® in HIV-negative; arm: 4 mg zoledronic acid annually plus conventional treatment in HIV-negative.
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Efficacy of 4 mg Zoledronic Acid Plus Colaren vs 4mg Zoledronic Acid + Conventional Treatment for Secondary Osteoporosis in HIV Positive and Negative Men
  • Actual Study Start Date: April 2019
  • Estimated Primary Completion Date: December 2019
  • Estimated Study Completion Date: February 2020
Arms and interventions
Arm Intervention/treatment
Experimental: 1 Arm: Experimental
Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man with HIV infection plus osteoporosis
Drug: Colaren in HIV positive
1 Arm (HIV+): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
Active Comparator: 2 Arm: Active comparator
Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man with HIV infection plus osteoporosis
Drug: standard treatment in HIV positive
2 Arm (HIV+): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
Experimental: 3 Arm: Experimental
Experimental: 4 mg zoledronic acid plus colaren ® This arm include: 20 man without HIV infection plus osteoporosis
Drug: Colaren in HIV negative
3 Arm (HIV-): will receive Zoledronic acid 4mg and colaren ® (vitamin D, magnesium, phosphate, calcium).
Active Comparator: 4 Arm: Active comparator
Active comparator: 4mg zoledronic acid + standard treatment (or conventional treatment) This arm include: 20 man without HIV infection plus osteoporosis
Drug: standard treatment in HIV negative
4 Arm (HIV-): will receive Zoledronic acid 4mg and standard treatment (vitamin D and calcium carbonate)
Outcome Measures
  • Primary Outcome Measures: 1. Change in Bone turnover markers (from baseline to 12 months under treatment) [ Time Frame: Time frame: from baseline, 3 and 12 months under treatment. ]
    Plasma measure of (through LEGENDplex (Multiplex)): Bone formation panel that include: Osteoprotegerin (OPG) measure in pg/mL, Alkaline Phosphatase Liver/Bone/Kidney (ALPL) measure in pg/mL, LEPTINA measure in pg/mL and Bone Morphogenetic Protein 2 (BMP-2) measure in pg/mL. Bone resorption panel that include: Osteopontin (OPN) measure in pg/mL, Acid Phosphatase 5 Tartrate Resistant (ACP5) measure in pg/mL, RANKL measure in pg/mL, Tumor Necrosis Factor Alpha (TNF-α) measure in pg/mL, Interleukin 6 (IL-6) measure in pg/mL, Parathyroid Hormone (PTH) measure in pg/mL, Interleukin 1 beta (IL-1β) measure in pg/mL, Dickkopf WNT Signaling Pathway Inhibitor 1 (DKK-1) measure in pg/mL.
  • 2. Change from baseline of Bone mineral density at 12 months [ Time Frame: Time frame: from baseline and 12 months under treatment. ]
    Bone mineral density through Dual-energy X-ray absorptiometry (DXA scan) measure. Classification: Normal: T-score ≥ -1.0 Osteopenia: -2.5 < T-score < -1.0 Osteoporosis: T-score ≤ -2.5 Severe osteoporosis: T-score ≤ -2.5 with fragility fracture
  • Secondary Outcome Measures: 1. Tolerability of colaren vs standard treatment (conventional treatment): grading the severity of Adult and Pediatric Adverse Events Version 2.0 [ Time Frame: Time frame: evaluate the tolerability from month 1, 3, 6, 9 and 12, under supplementation ]
    Evaluation of tolerability of Colaren and conventional treatment through the "Division of AIDS table for grading the severity of Adult and Pediatric Adverse Events Version 2.0, November 2014" Grade 1= Mild Grade 2= Moderate Grade 3= Severe Grade 4= Potentially
Eligibility Criteria
  • Ages Eligible for Study: 18 to 65 Years (Adult, Older Adult)
  • Sexes Eligible for Study: Male
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Adult males 18 to 65 years old.

- HIV diagnosis (HIV positive group) or negative HIV serology (HIV negative group).

- Patients receiving HAART and sustained virologic control for at least two years.

- Patients meeting diagnostic criteria for osteoporosis.

- Subjects willing to participate voluntarily in this study and give a written consent.

- Estimated glomerular filtration rate >60 mL/min (Using CKD-EPI formula).

Exclusion Criteria:

- Use of calcium, vitamin D or any other drug with bone activity during the last 90 days
previous to the study.

- Use of herbs or herb products during the last 90 days previous to the study.

- Positive test for HCV or HBV.

- Patients who cannot be submitted to complete examination for variable analysis.

- Glomerular filtration rate <60 mL/minute. - Active liver disease. - Non-compliance to treatment (less than 90%). - Patients who are not willing to continue participating. Non-inclusion criteria: - Female patients. - Use of immunosuppressive o immunomodulatory treatment 90 days previous to selection. - Use of prohibited drugs for the study like: antiestrogens, corticosteroids (doses greater than 7.5mg of prednisone/day) 90 days previous to selection. - Use of hormone therapy. - Patients with history or actual use of chemotherapy. - Patients deprived of freedom or imprisoned patients with mental illnesses. - Participant is part of another clinical trial or nutritional program. - Hypogonadism diagnosis with not having received hormonal replacement previous to the study. - Primary osteoporosis diagnosis.

Contacts and Locations
Contacts

Contact: Luz A González-Hernández, PhD +52 3336147586 lagonzalez@hcg.gob.mx

Contact: Jaime F Andrade-Villanueva, MD +52 3336145501 drjandradev@cucs.udg.mx

Locations

Mexico, Jalisco
Hospital Civil de Guadalajara Fray Antonio Alcalde
Guadalajara

Sponsors and Collaborators

University of Guadalajara

Hospital Civil de Guadalajara

More Information